Immune Checkpoint Inhibitors Market Regulations and Competitive Landscape Outlook to 2027 April 2017 Report Id : REP-GB-3326 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices ©2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Customized Research Syndicated Research Investment Research Social Media Research Customized Research Syndicated Research Investment Research Social Media Research Sector Coverage Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Subscription Information For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: [email protected] ©2015 Future Market Insights, All Rights Reserved 2 Research Methodology (1/2) Systematic Research Approach 1 Market profiling 2 Formulating discussion guide 3 Developing list of respondents 4 In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. PMR formulates a detailed discussion guide to conduct expert and industry interviews PMR develops a list of industry players (manufacturers), distributors, retailers and industry experts Data collection PMR conducts interviews with industry experts, industry players, distributors and retailers Data validation Data is validated by triangulation method, wherein secondary, primary and PMR analysis contribute to the final data 5 6 Data analysis Insights 7 Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry PMR delivers industry insights and information in the required format (PDF) Data Collection Research & Intelligence Data Filter & Analysis Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain Actionable Insights A Primary Research B SOLUTION Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments Primary Research # Linkedin Zoominfo Salesforce Avention Business Solution Desk Research C Key industry experts Channel study Developments Market dynamics Products Conclusions Company Analysis Secondary Research # Company websites Company annual reports White papers Financial reports Paid Publications# Factiva GBI Genios Meltwater # includes sources of databases ©2015 Future Market Insights, All Rights Reserved 3 Immune Checkpoint Inhibitors Market Regulations and Competitive Landscape Outlook to 2027 Cancer is the leading cause of death worldwide and hence offers a lot of unmet research areas yet to be targeted. The field of oncology is wide comprising a varied type of application area. The focus of researchers is gradually shifting towards the immunotherapies. The immunotherapy makes the use of body’s own components to fight cancer. Immune checkpoints are molecules that stimulate or inhibit the immune cells. Yervoy was the first drug launched in the immune checkpoint inhibitors domain. This anitCTLA-4 drug was followed by many other drugs such as Keytruda and Opdivo. Besides these molecules there are several others under clinical development. There is an ongoing competition between the immune checkpoint inhibitors market contributors to emerge as a leader. Immune Checkpoint Inhibitors Market: Drivers and Restraints The immune checkpoint inhibitors market is driven by the number of research developments undertaken by industry contributors as well as academic institutes. The immune checkpoint inhibitors market is experiencing a lot of collaborations wherein companies are combining their core competencies to fasten their research programs. For instance, Merck known as MSD outside the U.S. and Canada along with Dynavax Technologies Corporation are investigating the potential synergistic effects by combining Dynavax's SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966. ©2015 Future Market Insights, All Rights Reserved 4 Immune Checkpoint Inhibitors Market Regulations and Competitive Landscape Outlook to 2027 Immune Checkpoint Inhibitors Market: Overview The immune checkpoint inhibitor market is driven by the need to address the rising rate of cancer prevalence thereby affecting the country healthcare cost. In UK, lung cancer is the leading cause of cancer related death. The survival rate past five years has only being 9% after the person is diagnosed with lung cancer. The new form of immunotherapy based on the inhibition of programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) receptors has shown hope as a therapy option for lung cancer. Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3326 Immune Checkpoint Inhibitors Market: Region-wise Outlook In terms of geography, immune checkpoint inhibitors market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. The number of clinical trials and research funding is relatively high in North America, making it the dominant region in terms of revenue in the immune checkpoint inhibitors market. In September 2014, Merck received accelerated FDA approval for its Keytruda molecule to treat patient with advanced melanoma. The company is forming global alliances with other companies to co-develop ©2015 Future Market Insights, All Rights Reserved 5 Immune Checkpoint Inhibitors Market Regulations and Competitive Landscape Outlook to 2027 immnuo-oncology research and expand its oncology business. Asia Pacific is the fastest growing region in the immune checkpoint inhibitors market as there are number of research collaborations of international players with companies from this region. For instance, BristolMyers Squibb received Japanese approval for Opdivo in 2014, through partnership with Ono Pharmaceuticals. Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3326 Immune Checkpoint Inhibitors Market: Key Market Participants Some of the market contributors to the immune checkpoint inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Merck KGaA, Ono Pharmaceutical Co., Ltd., Novartis International AG, Juno Therapeutics and Kite Pharma. ©2015 Future Market Insights, All Rights Reserved 6 To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: [email protected] For media queries, contact the press office at [email protected] For other queries contact: Harish Tiwari (General Manager & Global Head Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: [email protected] Thank You Future Market Insights Global & Consulting Private Limited (FMI) ©2015 Future Market Insights, All Rights Reserved 7
© Copyright 2024